ArticleBMC women's health2025
Impact of diagnosis-to-treatment interval on mortality in patients with early-stage breast cancer: a retrospective nationwide Korean cohort.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Breast cancer burden among women of reproductive age in China, Japan, and South Korea, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.International journal of clinical oncology · 2026Article
- Socio-Demographic Inequalities in Diagnostic Delays of Breast Cancer: A Multistage Time-to-Diagnosis Analysis.Current oncology (Toronto, Ont.) · 2025Article
- Measuring Surgical Waiting Times in Breast Cancer: Admission to Surgery Versus Biopsy Result to Surgery.Healthcare (Basel, Switzerland) · 2025Article
- The delayed cancer treatment and economic inequality in Korea: results of common cancers by the time-to-surgery.Epidemiology and health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe diagnosis-to-first-treatment interval (DFTI) is an important prognostic factor and a major concern for patients with breast cancer as well as their clinicians. It may be particularly important for patients with early-stage breast cancer. The aim of this study was to investigate the association between DFTI and risk of mortality in patients with new-onset early-stage breast cancer.
methodsThis nationwide, retrospective cohort study utilized data from the Korean National Health Insurance database and the Korea National Cancer Incidence Database (2006-2017). By using 1:5 propensity score matching, 3,625 participants with a DFTI < 60 days and 725 with a DFTI ≥ 60 days were included in the analysis. Cox proportional hazard regression models were used to examine the association between the DFTI and 5-year all-cause mortality risk.
resultsCompared with patients with breast cancer with a DFTI < 60 days, patients with a DFTI ≥ 60 days had a higher 5-year mortality risk (hazard ratio [95% confidence interval], 2.09 [1.43-3.06]). Similarly, sensitivity analysis with a 45-day threshold revealed higher mortality in patients with a DFTI ≥ 45 days (HR [95% CI], 1.49 [1.14-1.96]) than their counterparts with a DFTI < 45 days. This association was greater for patients with low household income, those who lived in rural areas, and those with a high Charlson comorbidity index.
conclusionsA DFTI ≥ 60 days was associated with mortality risk in patients with early-stage breast cancer. These results emphasize the importance of closely monitoring the waiting times of this patients population and ensuring timely treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.